Grand Pharma
Headquartered in Wuhan, China, Grand Pharmaceutical Group Limited (00512.HK) has been publicly listed on the Hong Kong Stock Exchange since 2008. We are committed to transforming patient outcomes, focusing on pharmaceutical drug development, nuclear medicine for tumor diagnosis and treatment and cerebro-cardiovascular precision intervention technologies. Grand Pharmaceutical Group covers a broad spectrum of business areas, including: Radiopharmaceutical diagnosis and therapy, Precision cardiovascular & neurovascular interventional therapies, Respiratory and critical care, Otorhinolaryngology (ENT), Emergency cardiovascular care, APIs, mRNA platform, and Amino acids. Grand Pharmaceutical continues to advance its “Go Global” innovation strategy, deploying a diverse portfolio of innovative drugs and medical devices originating from the United States, Australia, Germany, Belgium, and other countries. We have established deep collaborations with leading global pharmaceutical companies, universities, and research institutions, forming a robust and diversified product pipeline focused on cutting-edge medical treatments. Globally, we have built and participated in five R&D technology platforms and eight R&D centers. Wuhan Optics Valley International R&D Center (China): Primary R&D hub in China, providing technical support for high-end formulation development; Australia R&D Center: Glycoscience technology platform focused on antiviral drug development; Nanjing R&D Center (China): mRNA technology platform focusing on oncology and anti-infective therapies, with future expansion into rare diseases and protein replacement therapies; Boston R&D Center (USA) and Chengdu Radiopharmaceutical R&D Center (China): Tumor interventional platform and radiopharmaceutical Radioisotope Drug Conjugate (RDC) technology platform; Wuhan Optics Valley Medical Device R&D Center, Changzhou Medical Device R&D Center, and Shanghai Medical Device R&D Center (China): High-end medical device technology platforms enabling innovation from design to commercialization.
Nuclear Medicine for Anti-Tumor Diagnosis and Treatment
Our radiopharmaceutical segment for anti-tumor diagnosis and therapy is one of the most globally integrated business areas within the Group. Centered on the concept of integrated cancer diagnosis and treatment, this segment currently has 15 globally innovative products in the R&D and registration stages, spanning 5 radioisotopes and targeting 7 types of cancer. At the early research stage, we have 12 Radioisotope Drug Conjugates (RDCs) under development. Covering both diagnostic and therapeutic applications, the portfolio provides multi-indication treatment options and comprehensive solutions that integrate diagnosis and therapy, delivering globally leading anti-cancer care. Driven by our “Go Global” development strategy, we have built a fully integrated global radiopharmaceutical industrial chain spanning R&D, manufacturing, distribution, and commercialization. With Boston and Chengdu as core R&D hubs and production capabilities deployed across Boston, Frankfurt, Singapore, and Chengdu, we have established a strong global supply network covering over 50 countries and regions. Our world-class radiopharmaceutical R&D and manufacturing base in Wenjiang, Chengdu, has obtained a Class A Radiation Safety License issued by China’s Ministry of Ecology and Environment. It is one of the most advanced smart factories worldwide, featuring the broadest radioisotope portfolio and the highest level of automation in the industry. This base further strengthens our industrial foundation, accelerates the global launch of innovative therapies, and supports high-quality development of the nuclear medicine sector, laying a solid foundation for the localization of radiopharmaceuticals and the creation of high-value blockbuster products.
Cerebro-Cardiovascular Precision Intervention Diagnosis and Treatment
Adhering to the concept of “intervention without implantation,” we have established a comprehensive product cluster of technology-driven high-end medical devices in three major directions: access management, structural heart disease, and heart failure. We have built a complete platform covering both passive and active innovative medical devices. Going forward, we aim to build this segment into a leading precision cardiovascular and neurovascular interventional therapy platform in China and globally.
We have a solid foundation in respiratory and critical care, ENT, and cardiovascular fields, with market-leading drugs and a robust pipeline of innovative products in development.
Respiratory and Critical Care
We leverage internal R&D and global strategic partnerships to build a comprehensive pipeline for chronic airway disease management and critical care, continuously reinforcing our leadership in these areas.
Eye, Nose, and Throat (ENT)
We uphold a development strategy that integrates traditional Chinese and Western medicine and combines pharmaceuticals and medical devices to strengthen our industry influence and drive breakthroughs across new therapeutic areas. Our treatments span multiple clinical specialties—including ophthalmology, otolaryngology, and dentistry—and cover chemical drugs, traditional Chinese medicine, and health products across prescription drugs, OTC products, medical devices, and consumer healthcare. Supported by a customer-centric and academically driven professional marketing team, we have established a nationwide commercial network.
Cerebro-Cardiovascular
We maintain a dual focus on acute rescue and chronic disease management, with over 20 pipeline products in development. Through a combination of independent innovation and high-barrier generic technology breakthroughs, we continue to expand and develop urgently needed therapies in cardiovascular and cerebrovascular emergency care and chronic disease treatment. In the emergency care segment, Grand Pharmaceutical has been designated as National Essential Medicines Manufacturing Base, Emergency Medicines Manufacturing Base, and National Small-Volume and Shortage Drug Centralized Production Base. We currently have over 30 product varieties, among which, 14 products are included in the China National Emergency Medicines List, and 16 products are listed in the National Drug Shortage List. Our portfolio size ranks among the top in the industry, covering in-hospital emergency care, pre-hospital rescue, and community emergency response, providing comprehensive rescue treatment solutions for multiple critical scenarios.
Active Pharmaceutical Ingredients (APIs)
Our API segment has developed a robust and diversified product pipeline with a strong cluster-based portfolio advantage, combining high-volume APIs with specialty APIs, supported by a global sales network. As a critical upstream component of our integrated API–formulation supply chain, we now operate multiple modern API manufacturing bases featuring advanced equipment, industry-leading processes, strong industrialization capabilities, and rigorous quality control systems. Focusing on five key therapeutic areas—cardiovascular & cerebrovascular, anti-infective, analgesic & antipyretic, gastrointestinal, and anticancer—we support the full lifecycle of drug product development and manufacturing within our pharmaceutical technology business. This ensures high standards and consistency in finished formulations, enabling true integration of upstream and downstream industrial advantages.
mRNA Technology
We focus on the development of mRNA therapeutics, particularly in oncology and anti-infective indications. We have successfully established both an mRNA production technology platform and a Lipid Nanoparticle (LNP) delivery technology platform. Our pipeline includes the therapeutic cancer vaccine ARC01 (A002), targeting HPV-16-positive solid tumors. In January 2024, ARC01 received approval in China to initiate Phase I clinical trials, making it the country's first mRNA therapeutic cancer vaccine approved for HPV-positive tumor trials.
We are a leading global supplier of high quality amino acids, committed to technological innovation and stringent quality assurance. We place strong emphasis on technological innovation and the development of a high-standard quality assurance system. We have obtained comprehensive domestic and international quality certifications and have been recognized with multiple national-level honors, including National Green Factory, National Manufacturing Single Champion Demonstration Enterprise, National Specialized and Innovative Enterprise, and National Intellectual Property Demonstration Enterprise.
Our biotechnology R&D team consists of over 90 researchers, with more than 200 invention patents granted. We have led or participated in the development of over 60 national, industrial, and association standards, nearly 50 of which have already been issued. We offer nearly 50 types of amino acids and derivatives, and possess 26 API registration certificates, the highest number in China for amino acid APIs. Our sales network extends to more than 140 countries and regions worldwide.